Premium
p‐Cymene Complexed in β‐Cyclodextrin to Cancer Pain Control
Author(s) -
Barreto Andre,
Guimarães Adriana,
Oliveira Marlange,
Serafini Mairim,
Araujo Adriano,
Barreto Rosana,
Quintans Jullyana,
QuintansJunior Lucindo
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.936.6
Subject(s) - nociception , p cymene , chemistry , hyperalgesia , pharmacology , cyclodextrin , palpation , receptor , medicine , biochemistry , surgery , ruthenium , catalysis
p‐Cymene (PC) is an alkylbenzene commonly found in cumin oil which has shown antinociceptive activity in animal models. Now, we evaluated the effect of encapsulation of PC in β‐cyclodextrin (PC/β‐CD) on nociception induced by tumor cells (sarcoma 180) in rodents. PC/β‐CD complex was administered (12.5 ‐ 50 mg/kg, p.o.) in mice with tumor (10 6 cells/25 mL, s.c.) on the hind paw, which were evaluated regarding hyperalgesia (digital von Frey apparatus), spontaneous and palpation‐induced nociception. The experimental protocols were approved by UFS Ethic Committee (CEPA: 19/11). PC/β‐CD (12.5, 25 e 50 mg/kg) was able to reduce significantly hyperalgesia (p < 0.001 or 0.05), and this effect was maintained for 24 hours after treatment. Oral administration of PC/β‐CD complex (12.5‐50 mg/kg) on alternate days also reduced spontaneous and nociception induced by palpation (p<0.001 ‐ 0.05). Free PC (50 mg/kg, p.o.) and PC no complexed with β‐CD, were unable promote significant changes in nociceptive responses. Therefore, results obtained suggest the inclusion complex containing p‐cymene and β‐cyclodextrin may improve the pharmacological characteristics of terpenoids or related compounds with potential applicability in chronic pain, such as cancer. Financial support: FAPITEC‐SE and CNPq (Brazil).